Robert D. McBane

TL;DR: This review explains management, including bridging anticoagulation for patients receiving warfarin, as well as how to manage the risks of bleeding versus the risk of thrombosis following invasive procedures.

TL;DR: In this article, the first 447 patients enrolled in a national FMD registry from 9 US sites were reviewed for clinical features, presenting symptoms, and vascular events, and the most common presenting symptoms of the disease were hypertension, headache, and pulsatile tinnitus.

TL;DR: In patients with nonvalvular atrial fibrillation, apixaban was associated with lower risks of both stroke and major bleeding, dabigatran was associated as with similar risk of stroke but lower risk of major bleed, and rivaroxaban wasassociated with similar risks ofBoth stroke andMajor bleeding in comparison to warfarin.

TL;DR: Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE) and apixaban is approved for the treatment of acute VTE.

TL;DR: Efficient, cost effective diagnosis of VTE is facilitated by combining medical history and physical examination with pre-test probability models, D dimer testing and selective use of confirmatory imaging, which offers the potential to customize VTE therapy for the individual patient.